Targeting the actin cytoskeleton (CSK) of cancer cells offers a valuable strategy in cancer therapy. There are a number of natural compounds that interfere with the actin CSK, but the mode of their cytotoxic action and, moreover, their tumor-specific mechanisms are quite elusive. We used the myxobacterial compound Chondramide as a tool to first elucidate the mechanisms of cytotoxicity of actin targeting in breast cancer cells (MCF7, MDA-MB-231). Chondramide inhibits cellular actin filament dynamics shown by a fluorescence-based analysis (fluorescence recovery after photobleaching (FRAP)) and leads to apoptosis characterized by phosphatidylserine exposure, release of cytochrome C from mitochondria and finally activation of caspases. Chondramide enhances the occurrence of mitochondrial permeability transition (MPT) by affecting known MPT modulators: Hexokinase II bound to the voltage-dependent anion channel (VDAC) translocated from the outer mitochondrial membrane to the cytosol and the proapoptotic protein Bad were recruited to the mitochondria. Importantly, protein kinase C-e (PKCe), a prosurvival kinase possessing an actin-binding site and known to regulate the hexokinase/VDAC interaction as well as Bad phosphorylation was identified as the link between actin CSK and apoptosis induction. PKCe, which was found overexpressed in breast cancer cells, accumulated in actin bundles induced by Chondramide and lost its activity. Our second goal was to characterize the potential tumor-specific action of actin-binding agents. As the nontumor breast epithelial cell line MCF-10A in fact shows resistance to Chondramide-induced apoptosis and notably express low level of PKCe, we suggest that trapping PKCe via Chondramide-induced actin hyperpolymerization displays tumor cell specificity. Our work provides a link between targeting the ubiquitously occurring actin CSK and selective inhibition of pro-tumorigenic PKCe, thus setting the stage for actin-stabilizing agents as innovative cancer drugs. This is moreover supported by the in vivo efficacy of Chondramide triggered by abrogation of PKCe signaling shown in a xenograft breast cancer model.
The actin cytoskeleton (CSK) plays a crucial role in intracellular transport processes, migration of cells and cytokinesis. These processes require a highly dynamic behavior of the actin CSK that involves polymerization and depolymerization of actin filaments. Monomeric actin (Gactin) polymerizes in a head-to-tail manner to form helical actin filaments (F-actin) and the equilibrium between G-actin and F-actin is tightly regulated by so-called actin-binding proteins. 1 Besides being pivotal for cell motility and division, there is some evidence that actin CSK is also involved in cell death induction, but the underlying mechanisms and signaling molecules are not identified in detail. 1 One interesting candidate linking the actin CSK and cell death is protein kinase C-e (PKCe), a serine-threonine kinase of the PKC family 2 known to contain an actin-binding site. 3 PKCe is distributed in several tissues like heart and brain, 4, 5 and it is also overexpressed in a broad range of tumor malignancies like breast, stomach and gliomas. [6] [7] [8] Because of its distinct functions in proliferation and prosurvival signaling processes, PKCe is an established oncoprotein and a promising target for anticancer therapy. 9, 10 In this context, PKCe affects targets that regulate cell survival such as the transcription factors NF-kB and Stat3 or the Bcl-2 protein Bad (Bcl2-associated death promoter). [9] [10] [11] [12] Bad is a proapoptotic BH3-only protein from the Bcl2-like gene family that is inactive when phosphorylated (Ser112) by kinases such as PKCe. 13 Moreover, PKCe controls the linkage between the glycolytic enzyme Hexokinase II (HkII) and the voltage-dependent anion channel (VDAC) in mitochondria that is thought to be specific for tumor cells. 12, 14 VDAC, a channel located in the outer mitochondrial membrane facilitating the transport of small molecules, and hexokinase II, phosphorylating glucose as a rate-limiting step in glycolysis, 15 are both discussed for their roles in malignancy. 15, 16 Importantly, not only VDAC/HkII interaction but also Bad contribute to the regulation of the mitochondrial permeability transition (MPT). 14, 17, 18 This cell death eliciting process is initiated by an increased permeability of the mitochondrial inner membrane causing a depletion of the mitochondrial membrane potential, a net water influx into the mitochondrial matrix ('swelling') and finally the distension and rupture of the outer membrane. [19] [20] [21] [22] [23] The outer membrane damage leads to the release of cytochrome C from the intermembrane space of mitochondria into the cytosol, activation of the initiator caspase 9 and finally to the induction of apoptosis. 24 Although several molecular aspects of the MPT are still under debate, several modulators of this process are known, for example, cyclosporin A as the 'proto-type' inhibitor of calcium-induced MPT. 25, 26 Roy et al. 17 showed that the dephosphorylated, active form of Bad leads to MPT, and also that VDAC is thought to participate in this process. 16 HkII binding to VDAC, on the other hand, stabilizes VDAC and prevents MPT and apoptosis.
14 Thus, disrupting the VDAC/HkII complex as well as activation of Bad could be attractive strategies to selectively kill tumor cells via the MPT. In this work we aimed to characterize and understand the molecular link between actin CSK and induction of apoptotic processes. To this end we hypothesized that PKCe possessing an actin-binding site could be a signaling molecule bridging actin CSK and cell death. We used Chondramide A (ChA), a myxobacterial cyclodepsipeptide isolated from Chondromyces crocatus that is 27 known to induce polymerization of actin, 27,28 as a chemical tool to potentially affect PKCe-mediated cell death induction. Chondramide has been shown to inhibit cancer cell proliferation, 28, 29 but closer mechanistic insights are not available.
In fact, our study shows that overpolymerization of actin CSK via Chondramide leads to inhibition of a tumor-specific PKCe signaling pathway, resulting in the induction of MPT and apoptosis in vitro as well as in a xenograft breast cancer mouse model in vivo. These data uncover the potential of actin-binding drugs in cancer therapy.
Results
Chondramide inhibits actin dynamics and induces apoptosis via the intrinsic pathway. The dynamics of globular and filamentous actin equilibrium have been analyzed using the fluorescence recovery after photobleaching (FRAP) technique: a distinct region of MCF7 mammary cancer cells transfected with green fluorescent protein (GFP)-tagged b-actin has been bleached by laser (488 nm) and the actin filament dynamics were observed by time lapse microscopy ( Figure 1b) . Untreated cells recover from photobleaching within seconds seen by the rapid disappearance of the bleached area (Figure 1b Besides affecting the actin CSK, ChA treatment (300 nM, 48 h) induces apoptosis in both MCF7 and MDA-MB-231 mammary cancer cells. Cell death was quantified using an Annexin V/PI co-staining assay (Figure 2a ). ChA treatment (300 nM, 24 h) leads to a depletion of mitochondrial membrane potential (DCm) analyzed by the use of the mitochondrial selective dye JC-1 (Figure 2b ). Fluorescence profiles of both cell lines show a shift toward green fluorescence of JC-1 (shift to the left) after ChA treatment, indicating a decrease in mitochondrial membrane potential. In line with disruption of mitochondrial membrane potential, ChA treatment (300 nM) results in a release of cytochrome C from the mitochondria in both cell lines. Figure 2c shows FACS analysis of cytochrome C remaining in the mitochondria of cells treated with ChA for 24 h compared with untreated cells. Accordingly, downstream signaling of cytochrome C release, namely activation of caspases, was evaluated. Western blot analysis shows a decrease of pro-caspase 9 and the cleavage of poly(ADP-ribose) polymerase (PARP), a well-known substrate of effector caspases, in cells treated with 300 nM ChA (24 h) (Figure 2d ). In sum, Figure 2 demonstrates that ChA induces cell death via the intrinsic apoptosis pathway.
Chondramide induces translocation of HkII from mitochondria and dephosphorylation of Bad pointing to a role of the MPT. As ChA depleted DCm and induced mitochondrial cytochrome C release in mammary cancer cells, both hallmarks of the MPT, we focused on major players involved in this process. VDAC, which is localized at the outer mitochondrial membrane, interacts with HkII, thereby negatively modulating MPT and preventing apoptosis. 15 We found that the binding of HkII and VDAC is impaired by ChA (Figure 3a ). HkII colocalizes with mitochondria shown as a distinct dot-like pattern in control cells. In contrast, cells treated with 300 nM ChA displayed a rather diffuse localization of HkII, suggesting a disruption of the mitochondrial VDAC/HkII interaction. Western blot experiments support this notion as decreased protein levels of HkII were found in the mitochondrial fraction of cells treated with ChA (300 nM, 6 and 24 h) (Figure 3b) .
Moreover, ChA affects a further regulator of the MPT, that is, the Bcl-2 protein Bad. 17 Protein level of Ser-112 phosphorylated, inactive Bad decreased dose dependently after treatment of cells with ChA (100 and 300 nM, 6 h) with constant total Bad protein levels (Figure 3c ). Consequently, in cells treated with ChA an intensified colocalization of Bad with mitochondria was observed in comparison with untreated cells (Figure 3d ), supporting the idea that proapoptotic, mitochondrial Bad is increased by chondramide because of abrogation of the inactive, phosphorylated form of Bad.
Finally, the involvement of the MPT in ChA-induced cell death was further supported by a set of experiments using isolated mitochondria of untreated and ChA-treated MDA-MB-231 cells. In mitochondria isolated from untreated and ChAtreated cells, MPT could be induced by 400 mM Ca 2 þ (data not shown). Importantly, cyclosporin A efficiently blocked the Ca 2 þ -induced loss of DCm (Supplementary Figure 1A) and confirms participation of the MPT in isolated mitochondria from control cells (Supplementary Figure 1B) . In contrast, isolated mitochondria from ChA-treated cells only weakly responded toward the inhibitory action of cyclosporin A. A progressing depletion of DCm coincided with an increasing extent of mitochondria that have undergone swelling (i.e., MPT) (Supplementary Figure 1A and 1B) .
Thus, by altering known modulators of the MPT, ChA leads to a release of cytochrome C from mitochondria. The MPTblocking HkII/VDAC interaction is disrupted, Bad localizes to mitochondria and cyclosporin A inhibition of the MPT is and cleavage of PARP as parameters for activation of caspase-9 and effector caspases, respectively, was performed using cells exposed to ChA (100 and 300 nM, 24 h). The graphs represent the quantitative analysis of the band intensities of Pro-caspase 9 and the PARP cleavage product. Blotting for GAPDH serves as loading control. A representative blot out of three is shown. Bars represent the mean ± S.E.M. of three independent experiments performed in triplicates, ***Po0.001 (one-way ANOVA, Bonferroni)
Actin disruption by Chondramide leads to apoptosis F Foerster et al abrogated, thus finally resulting in inhibition of cytochrome C release.
ChA inhibits PKCe activation by trapping in actin bundles. Ser112-phosphorylation of Bad as well as the interaction of HkII with VDAC are known to be regulated by PKCe. 17 As PKCe contains an actin-binding site, our working hypothesis focused on PKCe as a link between the effect of ChA on actin CSK and the induction of apoptosis via mitochondrial activation. As a first step to verify this idea, the postulated interaction of actin CSK and PKCe was confirmed ( Figure 4 ). Immunostaining of mGFPb-actin-transfected MCF7 cells showed an enrichment of PKCe in ChA-induced actin bundles at 6 and 24 h after treatment ( Figure 4a ). To control that we are not observing a compound-specific effect of ChA, two other actinpolymerizing agents (jasplakinolide and doliculide) were used in this colocalization assay, and also here it could be shown that PKCe is trapped in actin bundles induced by jasplakinolide and doliculide (Supplementary Figure 2) . Interestingly, PKCa, which does not contain an actinbinding site, shows no colocalization in ChA-induced actin lumps (Supplementary Figure 3) . Analysis of cytosolic and cytoskeletal fractions of MDA-MB-231 ( Figure 4b ) and MCF7 cells (Supplementary Figure 4) showed increased actin content in the CSK fraction after ChA treatment compared with control cells that, importantly, is accompanied by enhanced PKCe protein levels, but not PKCa. GAPDH in the cytoskeletal fraction serves as impurity control for cytoplasmic contaminants. These data point to a specific interaction between actin CSK and PKCe and its modulation via ChA treatment. In fact, ChA affects activation of PKCe, as shown in Figure 4c . As translocation of PKCs to the cell membrane is a typical hallmark for their activation, MDA-MB-321 cells were stained for PKCe after exposure to phorbol-13-myristate-12-acetate (PMA), a common inducer of PKCs (1 mM, 30 min). PMA-stimulated cells clearly display PKCe protein localized on the cellular membrane, whereas treatment with ChA results in a significant decrease of PKCe at the plasma membrane quantified by counting the respective cells (Figure 4c ). Taken together, Figure 4 displays a trapping of PKCe and impaired PKCe activation as consequence of ChA-induced polymerization of actin CSK.
ChA-induced cell death is dependent on PKCe expression. In order to prove the link between PKCe and ChA-induced apoptosis, cells overexpressing PKCe were analyzed for their apoptotic response upon ChA treatment (Figure 5a ). Overexpression of PKCe was verified by western blot analysis (insets; Figure 5a (Figure 5d ). In sum, ChAinduced apoptosis is mediated by actin CSK disruption and is highly depending on the expression of PKCe in cells.
Chondramide reduces tumor growth and induces actin polymerization, PKCe trapping and apoptosis in vivo. Using a MDA-MB-231 xenograft mouse model administration of 0.75 mg/kg, Chondramide was shown to significantly reduce tumor growth as monitored by tumor volume (Figure 6a ). Tumor tissue was examined for apoptotic cells (TUNEL assay) and showed a significant increase of apoptotic nuclei in the Chondramide-treated group compared with control tissue (Figure 6b ). Furthermore, we analyzed actin CSK and PKCe in cryosections of tumor tissue. Chondramide also leads in vivo to a disruption of actin CSK (especially on the border of tumors) and, moreover, PKCe is localized in actin bundles in Chondramidetreated tumors (Figure 6c ). In sum, this set of experiments confirms Chondramides' cell death-inducing mechanism in vivo. The cartoon in Figure 6d summarizes the postulated molecular mechanism of Chondramide's mode of action.
Discussion
The actin and microtubule cytoskeletons play pivotal roles in cancer biology as they regulate tumor relevant processes, for example, cell cycle, morphogenesis or migration. 30 Whereas drugs such as vinca alkaloids or taxanes that target microtubules are well established in the clinic, 31 compounds binding to the actin CSK are still far away from their therapeutical application. One reason might be lack of knowledge on their tumor-specific mechanism of action.
The data communicated here provide a conceptual framework for actin-polymerizing agents such as Chondramide as tumor cell-specific cytotoxic drugs. The major findings were as follows. (1) The actin CSK is involved in specific apoptotic signaling via PKCe and regulation of MPT. As PKCe is overexpressed in tumor cells, a tumor cell-selective mode of action is proposed. (2) Actin-targeting Chondramide masters the challenge of isoform-specific inhibition of PKC, namely protumorigenic PKCe. (3) Chondramide induces apoptosis and displays in vivo efficacy via disruption of PKCe signaling.
Pharmacological interruption of actin dynamics has been reported before to lead to cell death, but the exact mechanisms remain unclear. 1 Posey et al. 32 hypothesized a role of gelsolin, an actin-binding protein, for apoptosis induced by another actin-polymerizing natural compound named jasplakinolide; however, gelsolin overexpression was shown to have no impact on apoptosis induction by jasplakinolide. We used Chondramide as a chemical tool to learn more about actin-specific apoptotic signaling. Chondramide, similar to jasplakinolide, 33 hyperpolymerizes the actin cytoskeleton, induces agglomeration of actin that assembles over time and forms massive amorphous actin bundles that contain actin-binding proteins as reported previously. 34 Our driving strategy was to search for regulators of cell death containing an actin-binding site and to examine whether they might be trapped within these actin structures and thereby display decreased functionality. We came up with PKCe, a member of the PKC family, that, on one hand, possesses an actin-binding motif 3, 5 and is, on the other hand, a crucial regulator of several prosurvival pathways. [6] [7] [8] [9] [10] [11] The PKC family has been an exciting target for drug discovery especially in cancer ever as they were identified as intracellular receptors for the tumor-promoting agents phorbol esters. 35 However, major challenges such as dissecting the contribution of PKC isozymes to cancer progression or developing modulators specific for the PKC isozymes are still to be met. PKCs are either pro-mitogenic or inhibit cell cycle progression depending on isozyme and cell type. PKCa and PKCD, for instance, promote anti-mitotic responses 36 in tumor cells, whereas PKCe is required for cancer cell survival. 10, 11 Furthermore, PKCe has been shown to be overexpressed in various types of cancer including breast cancer, 6,9 supported by our own data. PKCe mediates oncogenic activities as it affects the activity of transcription factors like ATF2, NF-kB and Stat3, 12, 37, 38 and also addresses distinct targets in the apoptotic machinery of cells such as the BH3-only Bcl2-family protein Bad. Bad exerts its pro-apoptotic functions in a dephosphorylated form and PKCe is known to directly phosphorylate Bad on serine 112, thus inhibiting the proapoptotic activity of Bad 17, 39, 40 by preventing MPT 17 and hence the onset of apoptosis. PKCe counteracts the MPT not only via inactivation of Bad but also by maintaining the complex of VDAC and HkII at the outer mitochondrial membrane. Phosphorylation of VDAC 4 as well as phosphorylation of the transcription factor ATF2, which then attenuates apoptosis through saving the VDAC/Hk interaction, 37 are discussed as mechanisms for the prosurvival features of PKCe. The association between the glycolytic enzyme HkII and VDAC has been reported to be specific for cancer cell mitochondria and thus its disruption promises tumor cellspecific apoptosis.
14 Inhibition of PKCe leads to MPT because of loss of VDAC/Hk complex as well as loss of inactivated Bad, both of which could be clearly demonstrated for Chondramide treatment. Our work provides evidence for MPT as target in apoptosis induction by PKCe inhibition in Chondramidetreated cells. Supplementary Data show that cyclosporin A, which normally blocks the Ca 2 þ -induced MPT, is not able to prevent mitochondrial swelling (i.e., the MPT) in isolated mitochondria from cells treated with Chondramide, thus further supporting the involvement of MPT. Moreover, our data offer an explanation of how changes in actin CSK dynamics lead to cell death and proposes actin CSK as a specific antitumor target. As mentioned above, identification of isozyme-selective modulators of PKCs has been a major challenge taken up by various approaches such as the development of ATPcompetitive small-molecule inhibitors that bind to the catalytic domain of the kinase, phorbol ester derivatives that mimic the binding of diacylglycerol or peptides that prevent the anchoring of the PKC to its RACK (receptor of activated C-kinase) that brings the activated enzyme to its substrate. 35 Our data propose Chondramide as an indirect PKCe-specific inhibitor based on the fact that particularly PKCe because of its actinbinding site is trapped by Chondramide-induced actin polymerization. The role of PKCe as a promising tumor-specific therapeutic target and as a major player in Chondramideinduced tumor cell death is supported by two facts. First, nontumor cells (MCF-10A breast epithelial cells) show low level of PKCe and are not sensitive to Chondramide. Second, PKCe overexpression, leading to free PKCe that is not trapped in actin bundles, rescues Chondramide-induced apoptosis.
Importantly, Chondramide shows in vivo efficacy. Treatment of mice bearing a xenograft breast tumor (MDA-MB-231 cells) with Chondramide leads to reduction of tumor growth by inducing apoptosis through PKCe trapping in actin bundles.
Our data link actin, a target distributed in all eukaryotic cells, to the cancer-specific protein PKCe and open new therapeutical approaches by using actin-overpolymerizing compounds. Thus, our work encourages comprehensive pharmacological evaluation of this class of actin-targeting agents in tumor therapy.
Materials and Methods
Reagents. Chondramide A (chemical structure Supplementary Figure 1) was isolated as described previously 29 and dissolved in dimethylsulfoxide (DMSO). The PKC activator PMA was purchased from Merck Millipore (Darmstadt, Germany) and dissolved in DMSO. Jasplakinolide was purchased from Sigma-Aldrich (Taufkirchen, Germany) and Doliculide was a gift from Professor Karl-Heinz Altmann (ETH Zurich, Zurich, Switzerland).
Cell culture. The human epithelial breast cancer cell line MCF7 was purchased from the DSMZ (Braunschweig, Germany) and maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS, Biochrom AG, Berlin, Germany), 1% pyruvate (Sigma-Aldrich), 125 mg/l insulin (Sigma-Aldrich), 1% nonessential amino acids (PAA, Pasching, Austria) and 1% penicillin/streptomycin (Sigma-Aldrich) at 371C and 5% CO 2 . MCF10-A nontumorigenic epithelial cells were from ATCC (Manassas, VA, USA) and cultivated in RPMI-1640 medium supplemented with 5% horse serum (PAA), Insulin 125 mg/l (Sigma-Aldrich), EGF 100 ng/ml (PeproTech, Hamburg, Germany), hydrocortisone 0.8 mg/ml (Sigma-Aldrich), cholera toxin 0.16 mg/ml (Sigma-Aldrich) Fluorescence recovery after photobleaching. MCF7 cells transfected with mGFP-b-actin were seeded in ibidi-m-slides (ibidi, Martinsried, Germany) and incubated in the climate chamber of a Zeiss LSM 510 (Zeiss, Jena, Germany) confocal microscope at 5% CO 2 , 371C. Regions of interest (ROIs) of equal size were chosen in untreated and ChA (300 nM, 0.5 h)-treated cells and were bleached by high laser energy (488 nm). Images were taken every 5 s, lasting for B2.5 min and the fluorescence intensity within the ROI was measured. Cells were randomly chosen for bleaching and quantification of fluorescence recovery was done using the LSM image browser software (Zeiss).
Quantification of cell death. For analysis of membrane phosphatidylserine exposure, phosphatidylserine switch to the outer leaflet of the plasma membrane was analyzed by Annexin-V staining using the respective apoptosis detection kit (ebioscience, San Diego, CA, USA) according to the manufacturer's instructions. Cells were analyzed by a FACSCalibur cytometer (Becton Dickinson, Heidelberg, Germany).
For propidium iodide exclusion assay, cells were harvested, washed, exposed to a solution of propidium iodide (50 mg/ml) (Sigma-Aldrich) in PBS and immediately analyzed by flow cytometry using a Becton Dickinson FACSCalibur.
Mitochondrial potential (DWm). Cells were harvested and incubated with JC-1 (Alexis Biochemicals, Loerrach, Germany; 1.25 mM, 371C, 30 min). Mitochondria with an intact potential display JC-1 red fluorescing aggregates, whereas in mitochondria with disrupted potential JC-1 is monomeric and green fluorescent. The shift in fluorescence was monitored by a FACSCalibur cytometer (Becton Dickinson) using channel FL1-H for green fluorescence. Membrane potential and swelling of isolated mitochondria was assessed by Rh123 fluorescence quenching as described in literature. 42 Cytochrome C release. Analysis of cytochrome C release was performed as previously described. 43 Briefly, cells were incubated in a digitonin-containing buffer for 30 min on ice (0.2 mM Na-EGTA, 100 mM KCl, 50 mg/ml digitonin, PBS), fixed with 4% PFA for 20 min and unspecific binding was blocked (3% BSA, 0.05% Saponine (Sigma-Aldrich), 1 h, RT) before incubation with cytochrome C antibody overnight at 41C and staining with the secondary antibody for 1 h. Cytochrome C antibody was purchased from Cell Signaling Technology (Danvers, MA, USA) and secondary goat-anti-rabbit-Alexa-488 antibody was obtained from Invitrogen (Darmstadt, Germany). Fluorescence was detected using a FACSCalibur cytometer (Becton Dickinson). A decrease in fluorescence intensity indicates a loss of mitochondrial cytochrome C that is washed out after cell membrane permeabilization.
Western blot analysis. Cells were harvested, washed and lysed on ice with a buffer containing 2 mM EDTA, 137 mM NaCl, 10% glycerol, 2 mM Na 4 P 2 O 7 , 20mM Tris-base, 1% Triton-X 100, 20 mM sodiumglycerolphosphate, 10 mM NaF, 2 mM Na 3 VO 4 , 1 mM phenylmethylsulfonylfluoride and Complete protease inhibitor (Roche, Mannheim, Germany). Equal amounts of protein were separated using SDS-PAGE and blotted on nitrocellulose membranes (GE Healthcare, Munich, Germany). Membranes were probed with antibodies as indicated. Following antibodies were used: actin (Merck Millipore), Bad/phospho-Ser112-Bad, b-Tubulin, Caspase 9, COX IV, Hexokinase II, PARP (Cell Signaling Technology), GAPDH, PKCa, PKCe (Santa Cruz Biotechnology, Dallas, TX, USA), goat-antimouse IRDye 800 cw (LI-COR Biosciences, Lincoln, NE, USA), goat-anti-rabbit-800 (Invitrogen), HRP goat-anti-mouse (Santa Cruz Biotechnology) and HRP-goat-anti-rabbit (Bio-Rad, Hamburg, Germany). For detection the enhanced chemiluminescence system (GE Healthcare) or the Odyssey infrared imaging system (LI-COR biosciences) was used.
Immunostaining and confocal microscopy. Cells were seeded in ibidi-m-slides (ibidi), treated as indicated, washed, fixed with 4% paraformaldehyde, permeabilized with 1% Triton-X 100 and incubated with 1% bovine serum albumin solution to block unspecific binding of antibodies. The following primary antibodies were incubated overnight at 41C: PKCa, PKCe (Santa Cruz Biotechnology) and Hexokinase II (Cell Signaling Technology). Goat-anti-rabbitAlexa647 antibody (Invitrogen) was used as secondary antibody and incubated with 0.5 mg/ml Hoechst 33342 (Sigma-Aldrich) for 2 h. Mitochondrial staining was achieved by using MitoTracker Red CMXROS (Invitrogen) according to the manufacturer's instructions. Stainings were visualized using the confocal microscope LSM 510 Meta (Zeiss).
Cell fractionations. For cytosolic-mitochondrial fractionation, mitochondrial fractions were prepared as previously described. 44 In brief, cells were harvested and lysed with a buffer containing digitonin (80 mg/ml) and centrifuged at 500 Â g to remove cell debris. Supernatants were collected and centrifuged at 12 000 Â g to separate the mitochondrial fraction from the cytosolic one. The pellet containing the mitochondrial fraction was washed with ice-cold PBS and permeabilized using 0.1% Triton-X 100. For functional analysis, mitochondria were isolated as described previously. 45 Protein content was determined via Bradford and equal amounts of protein were separated using SDS-PAGE.
For cytosolic-cytoskeletal fractionation, cytoskeletal preparation was modified from Zeidman et al. 5 Briefly, cells were lysed for 20 min on ice with the lysis buffer mentioned in the western blot section. Lysates were centrifuged at 500 Â g for 10 min to remove nuclei and cell debris. Supernatants containing cytosolic and cytoskeletal proteins were centrifuged at 12 000 Â g for 15 min to separate CSK. Proteins of supernatant and CSK pellet were separated using SDS-PAGE and blotted on nitrocellulose membrane (GE Healthcare).
Overexpression of PKCe. FLAG.PKCepsilon plasmid was a gift of Alex Toker 46 (Addgene plasmid 10795). MCF7 cells were transfected using the Amaxa Nucleofector kit V (Lonza) according to the manufacturer's instructions. MDA-MB-231 cells were transfected using FuGene HD transfection kit (Promega). pcDNA3.1 (Invitrogen) was used as empty vector control. Upregulation of PKCe was confirmed on protein level via western blot. At 24 h after transfection, cells were treated with ChA at indicated concentrations. Downregulation of PKCe. MDA-MB-231 cells were transfected for 72 h using Dharmafect transfection reagent (GE Heatlthcare, Buckinghamshire, UK) according to the manufacturer's instructions. The siRNA used for the experiments was ON-TARGETplus PRKCE siRNA from Dharmacon (GE Healthcare).
Staining of mammary tissue sections. Tumor and healthy breast tissues were fixed in formalin and embedded in paraffin blocks. Sections were stained with anti-PKCe antibody (Abcam, San Francisco, CA, USA) and visualized with the Vectastain ABC Kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instructions. Four control tissues and six tumor tissues were analyzed and images were taken on an Olympus BX41 microscope (Olympus, Center Valley, PA, USA) with a 20-fold magnification.
In vivo mouse xenograft model. 
